SpeeDx. Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. “SpeeDx’s molecular diagnostic solutions are having a profound global impact in the areas of STIs, antibiotic resistance markers, and respiratory diseases,” said Michael P. Rubin,…